Avoro Capital Advisors LLC Buys 1,349,999 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Avoro Capital Advisors LLC grew its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 7.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,999,999 shares of the company's stock after acquiring an additional 1,349,999 shares during the quarter. Taysha Gene Therapies comprises 0.5% of Avoro Capital Advisors LLC's holdings, making the stock its 28th largest holding. Avoro Capital Advisors LLC owned 9.76% of Taysha Gene Therapies worth $34,600,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of TSHA. Cibc World Markets Corp bought a new stake in Taysha Gene Therapies during the fourth quarter worth $28,000. E Fund Management Co. Ltd. bought a new stake in shares of Taysha Gene Therapies in the 4th quarter worth $31,000. AXQ Capital LP purchased a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at about $39,000. Tower Research Capital LLC TRC lifted its position in shares of Taysha Gene Therapies by 268.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 51,085 shares of the company's stock valued at $88,000 after purchasing an additional 37,233 shares in the last quarter. Finally, Mariner LLC boosted its holdings in Taysha Gene Therapies by 337.5% during the fourth quarter. Mariner LLC now owns 58,342 shares of the company's stock worth $101,000 after purchasing an additional 45,006 shares during the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Stock Performance

Shares of TSHA traded up $0.04 during mid-day trading on Wednesday, hitting $1.82. The stock had a trading volume of 3,992,602 shares, compared to its average volume of 2,701,241. Taysha Gene Therapies, Inc. has a 52 week low of $1.05 and a 52 week high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The business has a fifty day moving average price of $1.54 and a 200-day moving average price of $1.80. The firm has a market cap of $373.20 million, a P/E ratio of 2.89 and a beta of 0.96.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on TSHA. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Chardan Capital reiterated a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $6.63.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.